Bacterial protein synthesis; 30S subunit of the bacterial ribosome; tetracycline antibiotic; hypoxia-inducible factor (HIF)-1α

OVCAR-3、SKOV-3 和 A2780 珍珠棉系的增殖和克隆形成活性受到盐酸米诺环素（0-100 μM，24-72 小时）的抑制 [3]。米诺环素盐酸盐（0-100 μM，24-48 小时）。在示波器中，盐酸米诺环素（0-100 μM，72 小时））会引起细胞周期 [3]。除了抑制 caspase 依赖性和 caspase 非依赖性细胞死亡外，直接神经保护还可能与线粒体异常和细胞色素 c 保护有关 [2]。盐酸米诺环素诱导缺氧诱导因子（HIF）细胞增殖的检测[3]

在雌性裸鼠中，每天一次静脉注射盐酸卵分泌素（0-30 mg/kg），持续四个星期，可抑制 OVCAR-3 肿瘤的生长[3]。在脑损伤动物模型中，盐酸米诺环素 (IP) 是一种强效药物，在腹腔内高剂量给药时表现出神经保护作用 [1]。盐酸米诺环素（0-40 mg/kg，IP，一次）可显着抑制 METH 诱导的小鼠过度运动和行为敏化 [2]。在暂时性大脑中动脉闭塞 (TMCAO) 模型中，盐酸米诺环素（静脉注射 3 和 10 mg/kg 一次）可有效减少梗塞面积 [1]。盐酸米诺环素（3-10 mg/kg，静脉注射一次）对血液的影响可能会因电位诱发的室性心律失常而减轻。标准 200 mg 剂量对人体的这种作用可能与线粒体 KATP 通道、PI3K/Akt 信号传导和 L 型水平 (3 mg/kg) 有关[1]。

细胞增殖检测[3]
细胞类型：人卵巢癌细胞系（OVCAR-1α抑制，以及up-p53蛋白和AKT水平的调节/mTOR/p70S6K/4E-BP1失活染料 [6]。3. SKOV-3 和 A2780）和原代细胞（HEK-293、HMEC、HUVEC、ATCC）
测试浓度：0、1、10、50 和 100 μM
孵育时间：24、48或72小时
实验结果：抑制OVCAR-3、SKOV-3的增殖和A2780细胞呈浓度依赖性，IC50值分别为62.0、56.1和59.5 μM。对 HEK-293 或 HUVEC 的活力没有影响。

---

蛋白质印迹分析[3]
细胞类型： OVCAR-3、SKOV-3 和 A2780 细胞
测试浓度： 0、 10、50 和 100 μM
孵育时间：72 小时
实验结果： Cyclins A、B 和 E 低表达水平。 caspase- 增加 3 个水平，在 100 μM 时增加超过 3.0 倍。米诺环素激活的 caspase-3 进而导致 PARP-1 的裂解。 Caspase-3 增加 PARP-1、p89 的降解产物。

---

细胞周期分析[3]
细胞类型： OVCAR-3、SKOV-3 和 A2

Animal/Disease Models: Female nude mice (6 weeks old, 9 mice per group, each mouse was injected with OVCAR-3 cells subcutaneously (sc) (sc) on the left side of the abdomen) [3]
Doses: 10 or 30 mg/kg
Route of Administration: Orally in drinking water Administration, starting on day 8 of cell inoculation, one time/day for 4 weeks.
Experimental Results: Inhibited OVCAR-3 tumor growth and diminished microvessel density in these female nude mice.

---

Animal/Disease Models: Male Balb/cAnNCrICrIj mice (8 weeks old, 23-30 g, methamphetamine (METH, 3 mg/kg) subcutaneously (sc) (sc) (sc) in a volume of 10 ml/kg) [2]
Doses: 0, 10 , 20 or 40 mg/kg
Route of Administration: intraperitoneal (ip) injection, once, 30 minutes before METH administration
Experimental Results: Significantly attenuated METH-induced hyperlocomotion and the development of behavioral sensitization in mice at 40 mg/kg. Did not exert any effect on the induction of METH-induced hyperthermia in mice. Significantly attenuated the reduction of DA and DOPAC in the striatum. Significantly attenuated the reduction of DAT-immunoreactivity in the mouse striatum. Significantly attenuated the increase in MAC1-immunoreactivity in the striatum after the administration of METH.

---

Animal/Disease Models: Male Sprague-Dawley rats (270-330 g, TMCAO model)[1]
Doses: 3 mg/kg and 10 mg/kg
Route of Administration: IV, once, 4, 5, or 6 hours post TMCAO
Experimental Results: Reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56% at doses of 3 mg/kg; significantly reduced infarct size at 5 hours by 40% at doses of 10 mg/kg and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction.

---

Animal/Disease Models: Male Sprague-Dawley rats (270-330 g)[1]
Doses: 3, 10, or 20 mg/kg
Route of Administration: IV, once
Experimental Results: Peak concentrations of serum levels of minocycline averaged 3.6, 13.0 and 28.8 mg/L with 3, 10 and 20 mg/kg doses respectively. The serum levels of minocycline at a 3 mg/kg dose (3.6 mg/L) were similar to that reported in humans after a standard 200 mg dose. Did not significantly affect hemodynamic and physiological variables.

Effects During Pregnancy and Lactation
◉ Overview of Medication Use During Lactation
Many reviews indicate that tetracyclines are contraindicated during lactation because they can cause staining of infant tooth enamel or deposition in bone. However, a careful review of existing literature suggests that short-term use of minocycline during lactation is unlikely to be harmful because the drug concentration in breast milk is low, and the infant's absorption of the drug is inhibited by calcium in breast milk. Short-term use of minocycline by lactating women is acceptable. As a theoretical precaution, long-term or repeated use during lactation should be avoided. The infant should be closely monitored for rashes and potential effects on the gut microbiota, such as diarrhea or candidiasis (thrush, diaper rash). There have been reports of minocycline causing darkening of breast milk. Topical application of minocycline by the mother to treat acne does not pose a risk to a breastfed infant.
◉ Effects on Breastfed Infants
No relevant published information was found as of the revision date.
◉ Effects on Lactation and Breast Milk
A woman who took 100 mg of minocycline twice daily for nearly 4 years experienced galactorrhea after taking perphenazine, amitriptyline, and diphenhydramine, with the milk turning black.
Another woman who breastfed for 18 months after weaning, occasionally producing small amounts of breast milk, then took 150 mg of minocycline orally daily. After 3 to 4 weeks, the expressed milk turned black. The iron content in the milk was more than 100 times higher than normal. Mammograms were normal.
In both cases, macrophages containing black iron-containing pigment were found in the breast milk. This pigment is believed to be an iron chelate of minocycline or its metabolites.

[1]. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004 Apr 26;4:7.

[2]. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1381-93.

[3]. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012 May;125(2):433-40.

[4]. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):380-6.

[5]. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80.

[6]. Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res. 2015 Jan 15;5(2):575-88.

[7]. Hu X, Wu B, Wang X, Xu C, He B, Cui B, Lu Z, Jiang H. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011 Mar 11;654(3):274-9.

Minocycline hydrochloride (oral) may cause developmental toxicity, depending on state or federal labeling requirements. It is a tetracycline analog with a 7-dimethylamino group lacking the five methyl groups and hydroxyl groups, and is effective against tetracycline-resistant staphylococcal infections. See also: Minocycline hydrochloride (note moved here). Treatment options for multidrug-resistant (MDR) Acinetobacter baumannii infections are extremely limited. Intravenous minocycline is effective against many MDR Acinetobacter baumannii strains, and the Clinical and Laboratory Standards Institute (CLSI) has established breakpoints to guide the interpretation of minocycline susceptibility testing results for Acinetobacter baumannii. Furthermore, intravenous minocycline has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Acinetobacter baumannii infections. A growing body of literature reports the successful use of intravenous minocycline in the treatment of severe MDR-resistant Acinetobacter baumannii infections, particularly hospital-acquired pneumonia. These results, coupled with the generally good tolerability of intravenous minocycline, support its use as a viable treatment option for MDR-resistant Acinetobacter baumannii infections. [5]

---

Hypoxia-inducible factor (HIF)-1α is a key cell survival protein under hypoxic conditions and is associated with tumor progression and angiogenesis. We recently found that the inhibitory effect of minocycline on ovarian tumor growth is associated with attenuation of vascular endothelial growth factor (VEGF). This paper reports a related laboratory study aimed at verifying whether these effects are a result of HIF-1α inhibition. In this study, we investigated the effects of minocycline on HIF-1 and its upstream pathway components in vitro using human ovarian cancer cell lines (A2780, OVCAR-3, and SKOV-3) to elucidate the mechanism of action of minocycline. At the same time, we treated mice carrying OVCAR-3 xenografts with minocycline to evaluate the efficacy of minocycline in the HIF-1 pathway in vivo. The results showed that minocycline negatively regulates HIF-1α protein levels in a concentration-dependent manner and induces its degradation through a prolyl hydroxylation-independent mechanism. In addition, the inhibition of HIF-1α is associated with the upregulation of endogenous p53, which is a tumor suppressor and has been shown to be involved in the degradation of HIF-1α. Further studies have shown that the effect of minocycline is not limited to proteasome degradation, but can also downregulate the translation of HIF-1α by inhibiting the AKT/mTOR/p70S6K/4E-BP1 signaling pathway. In mice with established ovarian tumors, minocycline treatment led to the inhibition of HIF-1α expression, while p53 protein levels were upregulated and the AKT/mTOR/p70S6K/4E-BP1 pathway was inactivated. These data reveal that minocycline, as a drug targeting the oncogenic factor HIF-1α, has potential therapeutic value in the treatment of ovarian cancer, and its mechanism of action involves multiple pathways. [6] Minocycline has been shown to protect the myocardium from ischemia-reperfusion injury. This study investigated the effect of minocycline on ischemia-induced ventricular arrhythmias in rats. Male rats under anesthesia received minocycline (45 mg/kg, intraperitoneal injection) once an hour before ischemia, concurrently with or without 2-(4-morpholino)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002, 0.3 mg/kg, intravenous injection, a PI3K inhibitor) and 5-hydroxydecanoic acid [5-HD, 10 mg/kg, intravenous injection, a specific inhibitor of mitochondrial ATP-sensitive potassium channels (K(ATP))], administered once 10 minutes before ischemia, followed by 30 minutes of ischemia. Ventricular arrhythmias were assessed. L-type Ca²⁺ currents were measured using patch-clamp technique. During the 30-minute ischemia period, minocycline significantly reduced the incidence of ventricular fibrillation (VF) (P<0.05). Compared with the myocardial ischemia group, minocycline significantly reduced the duration of ventricular tachycardia with ventricular fibrillation (VT+VF), the number of VT+VF episodes, and the severity of arrhythmias (all P<0.05). Administration of LY294002 or 5-HD eliminated the protective effect of minocycline on the incidence of ventricular fibrillation, duration of VT+VF, number of VT+VF episodes, and severity of arrhythmias (all P<0.05). In addition, minocycline inhibited L-type Ca²⁺ currents in normal myocardial cell membranes in a dose-dependent manner. This study suggests that minocycline may alleviate ischemia-induced ventricular arrhythmias in rats through the PI3K/Akt signaling pathway, mitochondrial K (ATP) channels, and L-type Ca²⁺ channels. [7]

C23H28CLN3O7

493.9373

493.161

C, 55.93; H, 5.71; Cl, 7.18; N, 8.51; O, 22.67

13614-98-7

Minocycline;10118-90-8; Minocycline hydrochloride;13614-98-7;Minocycline-d6;1036070-10-6; 128420-71-3 (HCl hydrate)

54685925

Light yellow to yellow solid powder

659.4ºC at 760mmHg

205-210° (dec)

352.6ºC

6.33E-28mmHg at 25°C

1.688

164.63

6

9

3

34

971

4

CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl

KDLQIOPKJDNQIM-YKWOUSISSA-N

InChI=1S/C23H27N3O7.ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;/h5-6,9,11,17,27-28,32-33H,7-8,24H2,1-4H3;1H/b22-16+;/t9-,11-,17+,23-;/m1./s1

(4S,4aR,5aS,12aR,E)-2-(amino(hydroxy)methylene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione hydrochloride

NSC 141993; Minocycline HCl; NSC 141993; Mynocine hydrochloride; NSC141993; NSC-141993; Periocline; Klinomycin; Minocin; Solodyn; Mynocine; Tri-mino; Vectrin; Ximino; Minomax; Minomycin chloride; Mynocine hydrochloride

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意： 请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~19.23 mg/mL (~38.93 mM)
H2O : ~9.09 mg/mL (~18.40 mM)

配方 1 中的溶解度: 7.69 mg/mL (15.57 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。